皓元医药
(688131)
| 流通市值：78.88亿 | | | 总市值：80.71亿 |
| 流通股本：2.06亿 | | | 总股本：2.11亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,619,063,344.9 | 1,055,549,087.12 | 504,874,103.59 | 1,880,046,769.14 |
| 营业收入 | 1,619,063,344.9 | 1,055,549,087.12 | 504,874,103.59 | 1,880,046,769.14 |
| 二、营业总成本 | 1,383,328,088.18 | 919,361,955.83 | 465,236,626.83 | 1,672,706,963.81 |
| 营业成本 | 848,692,363.99 | 576,595,146.66 | 298,884,459.07 | 1,030,874,345.27 |
| 税金及附加 | 8,711,014.25 | 4,886,237.81 | 2,215,816.05 | 7,683,984.38 |
| 销售费用 | 153,373,226.19 | 97,504,233.7 | 43,702,221.81 | 158,023,343.9 |
| 管理费用 | 175,472,795 | 114,640,604.22 | 57,367,597.11 | 220,159,727.04 |
| 研发费用 | 172,412,405.7 | 112,161,480.92 | 53,593,858.98 | 224,115,452.97 |
| 财务费用 | 24,666,283.05 | 13,574,252.52 | 9,472,673.81 | 31,850,110.25 |
| 其中:利息费用 | 21,690,759.65 | 14,232,513.05 | 6,725,881.87 | 23,703,771.82 |
| 其中:利息收入 | 4,953,820.59 | 3,266,724.17 | 1,768,224.98 | 3,208,380.06 |
| 加:投资收益 | -5,034,621.27 | -5,245,231.45 | -2,138,700.84 | -4,772,110.67 |
| 资产处置收益 | -91,866.73 | -30,736.19 | 4,147.86 | 62,704.26 |
| 资产减值损失(新) | -77,892,250.97 | -49,903,371.19 | -22,127,152.32 | -83,999,102.8 |
| 信用减值损失(新) | -13,545,184.25 | -8,343,554.85 | -2,425,005.66 | -12,232,235.34 |
| 其他收益 | 18,589,528.22 | 5,812,609.17 | 3,643,034.56 | 21,929,523.47 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 157,760,861.72 | 78,476,846.78 | 16,593,800.36 | 128,328,584.25 |
| 加:营业外收入 | 457,098.15 | 310,187.98 | 129,653.98 | 2,340,274.15 |
| 减:营业外支出 | 385,253.44 | 146,192.96 | 23,324.83 | 2,476,314.44 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 157,832,706.43 | 78,640,841.8 | 16,700,129.51 | 128,192,543.96 |
| 减:所得税费用 | 17,053,051.02 | 9,721,948.3 | 163,959.67 | 1,884,939.97 |
| 六、净利润 | 140,779,655.41 | 68,918,893.5 | 16,536,169.84 | 126,307,603.99 |
| 持续经营净利润 | 140,779,655.41 | 68,918,893.5 | 16,536,169.84 | 126,307,603.99 |
| 归属于母公司股东的净利润 | 143,347,970.22 | 70,407,685.66 | 16,757,351.46 | 127,449,113.65 |
| 少数股东损益 | -2,568,314.81 | -1,488,792.16 | -221,181.62 | -1,141,509.66 |
| (一)基本每股收益 | 0.68 | 0.33 | 0.11 | 0.85 |
| (二)稀释每股收益 | 0.68 | 0.33 | 0.11 | 0.85 |
| 八、其他综合收益 | 14,035,099.29 | 12,837,511.63 | 347,032.14 | 827,004.88 |
| 归属于母公司股东的其他综合收益 | 14,035,099.29 | 12,837,511.63 | 347,032.14 | 827,004.88 |
| 九、综合收益总额 | 154,814,754.7 | 81,756,405.13 | 16,883,201.98 | 127,134,608.87 |
| 归属于母公司股东的综合收益总额 | 157,383,069.51 | 83,245,197.29 | 17,104,383.6 | 128,276,118.53 |
| 归属于少数股东的综合收益总额 | -2,568,314.81 | -1,488,792.16 | -221,181.62 | -1,141,509.66 |
| 公告日期 | 2024-10-30 | 2024-08-29 | 2024-04-30 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |